DOI: http://dx.doi.org/10.18203/2349-2902.isj20202813

Routine baseline serum carcinoembryonic antigen as a negative predictor of peritoneal metastasis in colorectal malignancies: a cost-effective tool in South India

D. Vinoth, Sunay N. Bhat, Joshua Samuel

Abstract


Background: Colorectal cancer, a formidable health problem worldwide has upto 8% synchronous peritoneal carcinomatosis. As only diagnostic laparoscopy can identify them, in countries with economic burden, selection of patients for laparoscopy is ideal. Our aim is to evaluate whether the baseline Carcinoembryonic antigen (CEA) is a good selection tool.

Methods: A retrospective study of 125 patients, who were diagnosed to have colorectal malignancy (any stage) and underwent elective surgery at our institution from 2012 till 2019 were included. The baseline serum CEA was compared with the intraoperative findings. The threshold levels of serum CEA compared were 6.5 and 100 ng/dl. The sensitivity, specificity, positive predictive value and negative predictive value for both thresholds were compared in 3 categories of patients, namely peritoneal metastasis (9 cases), metastasis to other organs (36 cases) and cases with no metastasis either in peritoneum or other organs (85 cases). The results were analysed using SPSS software.

Results: The mean age was 65, sex ratio (male:female) was 72:53. The sensitivity, specificity, positive predictive value, negative predictive value (NPV) for CEA threshold of 6.5 ng/dl was 44.44%, 60.34%, 8% and 93.33% for category 1. For CEA threshold of 100 ng/dl, it was 33.33%, 97.41%, 50% and 94.95% for category 1. NPV was 96.55% for category 3 (the highest value).

Conclusions: If the baseline CEA levels are less than 100 ng/dl,   96.55% of cases will not require a diagnostic laparoscopy. This hopefully will cut down the cost of unnecessary diagnostic laparoscopies, and reduce the morbidity of unnecessary laparotomies.


Keywords


Carcinoembryonic antigen, Peritoneal metastasis, Diagnostic laparoscopy, Colorectal malignancies, Cost, India

Full Text:

PDF

References


Globo Bibliography Can 2008. Available at http://globocan.iarc.fr/factsheets/cancers/colorectal.asp; 2008. Accessed on 3 March 2020.

NCRP (2013). Three years report of the population-based cancer registries 2009-2011. National cancer registry programme, Indian council of medical research (ICMR), Bangalore, India; 2013.

Finlay A, Johanna B. Clinical presentation, diagnosis, and staging of colorectal cancer. Waltham, Mass.: upto date, 2018. Available at https://www.uptodate.com/contents/clinical-presentation-diagnosis-and-staging-of-colorectal-cancer. Accessed on 3 March 2020.

Massalou D, Benizri E, Chevallier A, Duranton-Tanneur V, Pedeutour F, Benchimol D, et al. Peritoneal carcinomatosis of colorectal cancer: Novel clinical and molecular outcomes. Am J Surg. 2017;213:377-87.

Sugarbaker PH. Colorectal cancer: Prevention and management of metastatic disease. Biomed Res Int. 2014;2014:782890.

Koppe MJ, Boerman OC, Oyen WJ, Bleichrodt RP. Peritoneal carcinomatosis of colorectal origin: Incidence and current treatment strategies. Ann Surg. 2006;243:212-22.

Fischer JP, Basta MN, Mirzabeigi MN. A Risk Model and Cost Analysis of Incisional Hernia After Elective, Abdominal Surgery Based Upon 12,373 Cases: The Case for Targeted Prophylactic Intervention. Ann Surg. 2016;263(5):1010-7.

Gan N, Jia L, Zheng L. A sandwich electrochemical immunosensor using magnetic DNA nanoprobes for carcinoembryonic antigen. Int J Molecular Sci. 2011;12 (11):7410-23.

Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful. Clin Chemistry. 2001;47(4):624-30.

Wood CB, Gillis CR, Blumgart LH. A retrospective study of the natural history of patients with liver metastases from colorectal cancer. Clin Oncol. 1976;2(3):285-8.

Tan GH, Teo MC, Chen W, Lee SY, Jie NDW, Tham CK, et al. Surgical management of colorectal peritoneal metastases: treatment and outcomes compared with hepatic metastases. J Gastrointest Cancer. 2013;44(2):170-6.

Rothbarth J, Velde VDC. Treatment of liver metastases of colorectal cancer. Ann Oncol. 2005;16(2):44-9.

Verwaal VJ, Ruth VS, Bree DE, Sloothen VGW, Tinteren VH, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol: Off J Am Soc Clin Oncol. 2003;21:3737-43.

Hasbahceci M. Use of serum and peritoneal CEA and CA19-9 in prediction of peritoneal dissemination and survival of gastric adenocarcinoma patients: are they prognostic factors. Ann R Coll Surg Engl. 2018;100(4):257-66.

Min YL. CEA as a risk factor in predicting ocular metastasis from colorectal cancer. J Cancer. 2020;11(1):51-6.

Huang CJ, Jiang JK, Chang SC, Lin JK, Yang SH. Serum CA125 concentration as a predictor of peritoneal dissemination of colorectal cancer in men and women. Medicine. 2016;95(47):5177.

Bagaria B, Sood S, Sharma R, Lalwani S. Comparative study of CEA and CA19-9 in esophageal, gastric and colon cancers individually and in combination (ROC curve analysis). Cancer Biol Med. 2013;10:148-57.

SEER Training Modules, Colo-rectal cancer. U. S. National Institutes of Health, National Cancer Institute. Available at https://training.seer.cancer. gov/colorectal/abstract-code-stage/keys/html. Accessed on 24 April 2010.

Rihimaki M, Hemminki A, Sundquist J, Hemminki K. Patterns of metastasis in colon and rectal cancer. Sci Rep. 2016;6:29765.